

Title Migraine Medication

Reference Number: RDF1600-23

Date of Response: 26/06/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

How many patients have been treated with the following drugs in the past 4 months:

- Erenumab (Aimovig) - any disease
- Eptinezumab (Vyepiti) - any disease
- Fremanezumab (Ajovy) - any disease
- Galcanezumab (Emgality) - any disease
- Rimegepant (Vydura) - any disease
- Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

Treatment	Condition	Total
Erenumab (Aimovig)	any disease	40
Eptinezumab (Vyepiti)	any disease	0
Fremanezumab (Ajovy)	any disease	135
Galcanezumab (Emgality)	any disease	14
Rimegepant (Vydura)	any disease	0
Botulinum Toxin (i.e., Botox, Dysport, Xeomin)	migraine ONLY	69